Biomarkers for Oncology
JH · Effective Oct 1, 2015
169 active Medicare policies list C43.0, and 16 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
Showing 100 of 169
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
16 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Showing 10 of 15 · All Aetna policies
| Policy | Effective | Status of C43.0 |
|---|---|---|
| ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) | Oct 26, 2023 | Covered |
| Aldesleukin (Proleukin) | Sep 21, 2023 | Covered |
| Bevacizumab for Non-Ocular Indications | Feb 20, 2024 | Covered |
| Brachytherapy | Jun 6, 2023 | Covered |
| Carbogen Inhalation Therapy | Jun 8, 2023 | Covered |
| Donor Lymphocyte Infusion | Sep 13, 2023 |
JM · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J6 · Effective Jul 15, 2026
JK · Effective Jul 15, 2026
JJ · Effective Jul 24, 2022
JM · Effective Jul 24, 2022
J15 · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
J6 · Effective Apr 1, 2019
JK · Effective Apr 1, 2019
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
J5 · Effective Oct 1, 2015
J8 · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J15 · Effective Aug 21, 2022
JE · Effective Aug 8, 2022
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J15 · Effective Jun 24, 2019
JE · Effective Feb 10, 2019
JF · Effective Feb 10, 2019
JJ · Effective Dec 3, 2018
JM · Effective Dec 3, 2018
J5 · Effective Aug 12, 2019
J8 · Effective Aug 12, 2019
J15 · Effective Dec 26, 2021
JE · Effective Jan 2, 2022
JF · Effective Jan 2, 2022
JJ · Effective Dec 26, 2021
JM · Effective Dec 26, 2021
J5 · Effective Dec 26, 2021
J8 · Effective Dec 26, 2021
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J15 · Effective Feb 10, 2020
JE · Effective May 17, 2020
JF · Effective May 17, 2020
JJ · Effective Feb 10, 2020
JM · Effective Feb 10, 2020
J5 · Effective Feb 9, 2020
J8 · Effective Feb 9, 2020
J15 · Effective Jul 27, 2020
JE · Effective Dec 26, 2022
JF · Effective Dec 26, 2022
JJ · Effective Feb 3, 2020
JM · Effective Feb 3, 2020
J5 · Effective Mar 15, 2020
J8 · Effective Mar 15, 2020
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JE · Effective Oct 8, 2018
JF · Effective Oct 8, 2018
J9 · Effective Oct 1, 2015
J6 · Effective May 1, 2017
JK · Effective May 1, 2017
J6 · Effective Jul 13, 2025
JK · Effective Jul 13, 2025
J9 · Effective Dec 12, 2021
JH · Effective Dec 12, 2021
JL · Effective Dec 12, 2021
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
| Genetic Testing | Feb 27, 2024 | Covered |
|---|
| Hyperthermia in Cancer Therapy | Feb 9, 2024 | Covered |
|---|
| Mohs Micrographic Surgery | Jun 22, 2023 | Covered |
|---|
| Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) | Feb 20, 2024 | Covered |
|---|
| Policy | Effective | Status of C43.0 |
|---|---|---|
| Low-Level Laser and High-Power Laser Therapy | Mar 15, 2026 | Covered |